Systemic sclerosis & Raynaud's
Impact of immunosuppression on development and outcome of systemic sclerosis-associated pulmonary arterial hypertension
Main finding · Development of PAHResult — go to the resultOdds ratio 0.74Authors' conclusion
In this retrospective monocentric study early treatment with mycophenolate was associated with reduced odds of developing SSc-PAH, while treatment with hydroxychloroquine showed a significant improvement in survival in patients with established SSc-PAH.
Study context
- Population
- Patients with systemic sclerosis (SSc) reviewed in a single centre; Pulmonary arterial hypertension (PAH) defined as pre-capillary pulmonary hypertension (mPAP ≥ 25mmHg, PVR >3WU, PCWP <15mmHg) without significant hypoxic component77 with PAH
- Participants
- 607 patients
- Exposure
- Early immunosuppression vs no early immunosuppression
- Outcome
- Development of PAH
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Odds ratio
0.74
P = 0.495
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Developing PAH, early MMF | OR for developing PAH 0.12 | P = 0.048 |
| Mortality, immunosuppressive treatment | HR for mortality 0.41 | P = 0.045 |
| Mortality, HCQ (only agent with an impact on survival) | HR for mortality 0.04 | P = 0.004 |
Original publication
Impact of immunosuppression on development and outcome of systemic sclerosis-associated pulmonary arterial hypertension. Clin Exp Rheumatol. Published 1 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →